Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer.
Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer.
复制标题
巨噬细胞抑制性细胞因子-1 作为 I 期和 II 期非小细胞肺癌的新型诊断和预后生物标志物
DOI：
10.4103/0366-6999.189052
复制
发表时间：
2016-09-05
影响因子：
6.1
通讯作者：
Sun KL
中科院分区：
文献类型：
--
作者：
Liu YN;Wang XB;Wang T;Zhang C;Zhang KP;Zhi XY;Zhang W;Sun KL
上皮性肿瘤患者血清巨噬细胞抑制性细胞因子-1（MIC-1）水平升高。本研究旨在评价血清MIC-1水平是否可以作为早期非小细胞肺癌（NSCLC）的一个候选诊断和预后指标。一项前瞻性研究入组了152例手术切除后随访的I-II期NSCLC患者。48例良性肺病（BPD）患者和105名健康对照者也被纳入研究。采用酶联免疫吸附试验测定血清MIC-1水平，并分析其与临床和预后特征的相关性。NSCLC患者血清MIC-1蛋白水平显著高于健康对照组和BPD患者（P均< 0.001）。在早期（I期和II期）NSCLC患者中发现MIC-1的阈值为1000 pg/ml，敏感性和特异性分别为70.4%和99.0%。血清MIC-1水平与年龄（P = 0.001）、性别（P = 0.030）和T分期（P = 0.022）相关。在早期预后差的患者中，血清MIC-1阈值为1465 pg/ml，敏感性和特异性分别为72.2%和66.1%。血清MIC-1水平高（≥1465 pg/ml）的NSCLC患者的总3年生存率低于血清MIC-1水平低的NSCLC患者（77.6%vs.94.8%）。多因素考克斯回归生存分析显示，高血清MIC-1水平是总生存期降低的独立危险因素（危险比= 3.37，95%可信区间：1.09-10.42，P = 0.035）。本研究提示，血清MIC-1可能是早期NSCLC患者诊断和预后的潜在生物标志物。
Increased level of serum macrophage inhibitory cytokine-1 (MIC-1), a member of transforming growth factor-β superfamily, was found in patients with epithelial tumors. This study aimed to evaluate whether serum level of MIC-1 can be a candidate diagnostic and prognostic indicator for early-stage nonsmall cell lung cancer (NSCLC). A prospective study enrolled 152 patients with Stage I–II NSCLC, who were followed up after surgical resection. Forty-eight patients with benign pulmonary disease (BPD) and 105 healthy controls were also included in the study. Serum MIC-1 levels were measured using an enzyme-linked immunosorbent assay, and the association with clinical and prognostic features was analyzed. In patients with NSCLC, serum protein levels of MIC-1 were significantly increased compared with healthy controls and BPD patients (all P < 0.001). A threshold of 1000 pg/ml of MIC-1 was found in patients with early-stage (Stage I and II) NSCLC, with sensitivity and specificity of 70.4% and 99.0%, respectively. The serum levels of MIC-1 were associated with age (P = 0.001), gender (P = 0.030), and T stage (P = 0.022). Serum MIC-1 threshold of 1465 pg/ml was found in patients with poor early outcome, with sensitivity and specificity of 72.2% and 66.1%, respectively. The overall 3-year survival rate of NSCLC patients with high serum levels of MIC-1 (≥1465 pg/ml) was lower than that of NSCLC patients with low serum MIC-1 levels (77.6% vs. 94.8%). Multivariate Cox regression survival analysis showed that a high serum level of MIC-1 was an independent risk factor for reduced overall survival (hazard ratio = 3.37, 95% confidential interval: 1.09–10.42, P = 0.035). The present study suggested that serum MIC-1 may be a potential diagnostic and prognostic biomarker for patients with early-stage NSCLC.